Author:
Lojanapiwat Bannakij,Pripatnanont Choosak,Choonhaklai Vorapot,Soontornpun Surithorn,Sriplakich Supon,Leewansangtong Sunai,Santi-ngamkun Apirak,Opanuraks Julin,Kongcharoensombat Wisoot,Na-Songkla Bhapapak,Raksakul Wiroj,Predanon Chagkrapan
Reference11 articles.
1. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015
2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016
3. European Association of Urology guideline version 2015 [Internet]. Available from: http://www.uroweb.org/guidelines/.
4. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015
5. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献